Outcomes
DLTs, TEAEs, Cancer
ADVERSE EVENTS, ADVERSE EVENT, SECONDARY, CANCER
In Phase 1, safety and tolerability were assessed based on DLTs in Cycle 1, treatment‐emergent adverse events (TEAEs) or serious TEAEs, and laboratory abnormalities. TEAEs and laboratory abnormalities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.Disease response was determined using positron emission tomography and assessed using the Lugano response criteria, 2014.Key secondary endpoints were duration of response (DoR) and progression‐free survival (PFS).The all‐treated population was the primary analysis population for efficacy and safety analyses and included all participants who received ≥1 Isa or Cemi dose.